Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Vectors Research Management LLC

Vectors Research Management LLC reduced its holdings in Thermo Fisher Scientific Inc. (NYSE:TMOGet Rating) by 1.9% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 8,622 shares of the medical research company’s stock after selling 170 shares during the quarter. Thermo Fisher Scientific accounts for 1.2% of Vectors Research Management LLC’s portfolio, making the stock its 19th largest position. Vectors Research Management LLC’s holdings in Thermo Fisher Scientific were worth $4,684,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the business. Grayhawk Investment Strategies Inc. acquired a new position in shares of Thermo Fisher Scientific during the 2nd quarter valued at $26,000. Advanced Research Investment Solutions LLC increased its position in shares of Thermo Fisher Scientific by 213.3% during the 1st quarter. Advanced Research Investment Solutions LLC now owns 47 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 32 shares during the period. Tortoise Investment Management LLC increased its position in shares of Thermo Fisher Scientific by 410.0% during the 2nd quarter. Tortoise Investment Management LLC now owns 51 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 41 shares during the period. Better Money Decisions LLC acquired a new position in shares of Thermo Fisher Scientific during the 2nd quarter valued at $29,000. Finally, Adirondack Trust Co. acquired a new position in shares of Thermo Fisher Scientific during the 2nd quarter valued at $34,000. 86.50% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock traded up $2.54 during trading on Thursday, reaching $547.29. The company had a trading volume of 823,632 shares, compared to its average volume of 1,753,300. The firm’s 50 day simple moving average is $517.90 and its two-hundred day simple moving average is $541.99. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.74 and a quick ratio of 1.22. Thermo Fisher Scientific Inc. has a one year low of $475.77 and a one year high of $672.34. The company has a market capitalization of $214.65 billion, a PE ratio of 30.76, a PEG ratio of 1.89 and a beta of 0.83.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, January 16th. Investors of record on Thursday, December 15th will be paid a $0.30 dividend. This represents a $1.20 dividend on an annualized basis and a dividend yield of 0.22%. The ex-dividend date of this dividend is Wednesday, December 14th. Thermo Fisher Scientific’s payout ratio is 6.75%.

Thermo Fisher Scientific declared that its Board of Directors has approved a stock buyback program on Thursday, November 10th that allows the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization allows the medical research company to repurchase up to 2% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s leadership believes its stock is undervalued.

Analysts Set New Price Targets

TMO has been the topic of several research analyst reports. Robert W. Baird lowered their price target on Thermo Fisher Scientific from $711.00 to $696.00 and set an “outperform” rating on the stock in a research report on Thursday, October 27th. Benchmark lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Thursday, October 27th. Barclays decreased their price target on shares of Thermo Fisher Scientific from $595.00 to $575.00 and set an “overweight” rating for the company in a report on Thursday, October 27th. Credit Suisse Group cut their target price on shares of Thermo Fisher Scientific to $620.00 in a research report on Thursday, October 27th. Finally, SVB Leerink dropped their target price on Thermo Fisher Scientific from $590.00 to $555.00 and set an “outperform” rating on the stock in a research report on Thursday, October 27th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the stock. According to MarketBeat, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus target price of $619.00.

Insider Activity at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 8,200 shares of the firm’s stock in a transaction that occurred on Thursday, November 3rd. The stock was sold at an average price of $487.45, for a total value of $3,997,090.00. Following the transaction, the chief executive officer now directly owns 178,005 shares of the company’s stock, valued at approximately $86,768,537.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 8,200 shares of Thermo Fisher Scientific stock in a transaction that occurred on Thursday, November 3rd. The stock was sold at an average price of $487.45, for a total value of $3,997,090.00. Following the transaction, the chief executive officer now directly owns 178,005 shares of the company’s stock, valued at approximately $86,768,537.25. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, October 31st. The stock was sold at an average price of $509.97, for a total value of $5,099,700.00. Following the completion of the transaction, the chief executive officer now directly owns 178,005 shares in the company, valued at $90,777,209.85. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 26,300 shares of company stock valued at $13,091,386. Corporate insiders own 0.43% of the company’s stock.

About Thermo Fisher Scientific

(Get Rating)

Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

See Also

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMOGet Rating).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.